Overview

Cold Challenge With C21 in RP

Status:
Completed

Trial end date:
2020-12-14

Target enrollment:

Participant gender:

Summary

This is a randomised, double-blind, placebo-controlled, cross-over phase 2 trial investigating the effect of C21 on cold-induced vasoconstriction in subjects with Raynaud's phenomenon secondary to systemic sclerosis. The purpose of the trial is to achieve a vasodilatory effect in subjects with Raynaud's phenomenon by stimulation of the AT2R with C21.

Phase:

Phase 2

Details

Lead Sponsor:

Vicore Pharma AB

Collaborator:

SGS Life Sciences, a division of SGS Belgium NV

Treatments:

Compound 21